Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-01-10
2010-02-02
Marschel, Ardin (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S080000
Reexamination Certificate
active
07655673
ABSTRACT:
The present invention relates to medical uses of 39-desmethoxyrapamycin.
REFERENCES:
patent: 5708002 (1998-01-01), Luly et al.
patent: 5712129 (1998-01-01), Ford
patent: 6485514 (2002-11-01), Wrenn, Jr.
patent: 2003/0176915 (2003-09-01), Wright et al.
patent: 2004/0147541 (2004-07-01), Lane et al.
patent: 2005/0032825 (2005-02-01), Metcalf et al.
patent: WO 93/16189 (1993-08-01), None
patent: WO 98/02441 (1998-01-01), None
patent: WO 2004/007709 (2004-01-01), None
patent: WO 2006/095173 (2006-09-01), None
Burkhardt et al. Rheumatol. Int., 1997, vol. 17, pp. 85-90.
Cecil, Textbook of Medicine, 21st Edition (2000), Goldman & Bennett (Editors), W.B. Saunders Company (Publisher), Chapter 198, pp. 1060-1074.
Dhooge C et al., “P-glycoprotein is an independent prognostic factor predicting relapse in childhood acute lymphoblastic leukaemia: results of a 60year prospective study,” 1999 British J Haematol. 105: 676-683.
Brown V, et al., “Rapamycin is active against B-precursor leukemai in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling,” 2003 PNAS 100(25): 15113-15118.
Gajra A, “Lymphoma, B-Cell,” eMedicine, Jan. 10, 2005, retrieved from the internet on Nov. 20, 2005 from http://emedicine.com/med/topic1358.htm.
Lowden, P.A.S., “New Rapamycin Derivatives by Precursor-Directed Biosynthesis,” ChemBioChem, 5:535-538, (2004).
Fu, L.W., et al., “The multidrug resistance of tumour cells was reversed by tetradrine in vitro and in xenografts derived from human brest adenocarcinoma MCF-7/adr cells,” European Journal of Cancer, 38:418-426, (2002).
Trepanier, D.J., et al., “Rapamycin: Distribution, Pharmacokinetics and Therapeutic Range Investigations: An Update,” Clinical Biochemistry, 31:345-351, (1998).
Gallant-Haidner, H.L., et al., “Pharmacokinetics and Metabolism of Sirolimus,” Therapeutic Drug Monitoring, 22:31-35, (2000).
Francois G. Roberge et al.; Treatment of Autoimmune Uveoretinitis in the Rat With Rapamycin, an Inhibitor of Lymphocyte Growth Factor Signal Transduction; Current Eye Research; vol. 2(2); pp. 197-203; 1993.
Deborah A. Young et al.; IL-4, IL-10, and IL-13, and TGF-β From an Altered Peptide Ligand-Specific TH2 Cell Clone Down-Regulate Adoptive Transfer of Experimental Autoimmune Encephalomyelitis; The Journal of Immunology; vol. 164; pp. 3563-3572; 2000.
Stephen J. Pettit et al.; Evaluation of Dendritic Cell Immunogenicity After Activation and Chemical Fixation: a Mixed Lymphocyte Reaction Model; vol. 25(2), pp. 152-161; 2002.
Sheridan Rose Mary
Zhang Mingqiang
Anderson James D
Biotica Technology Limited
Carango Paul
Herman Michael J.
Marschel Ardin
LandOfFree
39-desmethoxyrapamycin, compositions and methods of use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 39-desmethoxyrapamycin, compositions and methods of use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 39-desmethoxyrapamycin, compositions and methods of use thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4200664